ADAP Stock Overview
A clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Adaptimmune Therapeutics plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.13 |
52 Week High | US$2.05 |
52 Week Low | US$0.42 |
Beta | 2.44 |
1 Month Change | -5.04% |
3 Month Change | -22.60% |
1 Year Change | 8.65% |
3 Year Change | -75.49% |
5 Year Change | -71.39% |
Change since IPO | -93.44% |
Recent News & Updates
Recent updates
Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Apr 26Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Apr 16Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Feb 22Adaptimmune: Drug Approval Now Imminent?
Feb 02Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Mar 08Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Nov 09Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Sep 20We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022
Aug 10Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics
Aug 03Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
Jun 29Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
Jun 19Adaptimmune Therapeutics: A Little More Patience May Be Profitable
Mar 06Circling Back On Adaptimmune Therapeutics
Dec 15We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Dec 02Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
Sep 29We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Aug 14Adaptimmune Therapeutics: T-Cell Therapy Pioneer Boasts A Deep Pipeline, ESMO Approaches
Jul 29Adaptimmune Therapeutics: Still The TCR Leader, And With Major Upcoming Catalysts
Jun 16Adaptimmune Therapeutics (ADAP) Investor Presentation - Slideshow
Jun 05Adaptimmune slips as Barclays initiates with an underweight rating
May 28We Think Adaptimmune Therapeutics (NASDAQ:ADAP) Can Easily Afford To Drive Business Growth
Apr 15Investors Who Bought Adaptimmune Therapeutics (NASDAQ:ADAP) Shares A Year Ago Are Now Up 101%
Mar 15Is Adaptimmune Therapeutics plc (NASDAQ:ADAP) Popular Amongst Institutions?
Feb 17Shareholder Returns
ADAP | US Biotechs | US Market | |
---|---|---|---|
7D | 7.6% | -0.4% | -0.6% |
1Y | 8.7% | 5.4% | 22.5% |
Return vs Industry: ADAP exceeded the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: ADAP underperformed the US Market which returned 22.5% over the past year.
Price Volatility
ADAP volatility | |
---|---|
ADAP Average Weekly Movement | 12.5% |
Biotechs Industry Average Movement | 10.7% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ADAP's share price has been volatile over the past 3 months.
Volatility Over Time: ADAP's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 449 | Ad Rawcliffe | www.adaptimmune.com |
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center.
Adaptimmune Therapeutics plc Fundamentals Summary
ADAP fundamental statistics | |
---|---|
Market cap | US$288.79m |
Earnings (TTM) | -US$163.41m |
Revenue (TTM) | US$18.36m |
15.7x
P/S Ratio-1.8x
P/E RatioIs ADAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ADAP income statement (TTM) | |
---|---|
Revenue | US$18.36m |
Cost of Revenue | US$126.51m |
Gross Profit | -US$108.15m |
Other Expenses | US$55.26m |
Earnings | -US$163.41m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.64 |
Gross Margin | -589.12% |
Net Profit Margin | -890.13% |
Debt/Equity Ratio | 0% |
How did ADAP perform over the long term?
See historical performance and comparison